Clear All
12393 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
83634-0208-10 83634-0208 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 1, 2026 In Use
83634-0206-51 83634-0206 Cyclophosphamide Cyclophosphamide 1.0 g/50mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous, Oral Feb 1, 2026 In Use
83634-0205-50 83634-0205 Cyclophosphamide Cyclophosphamide 500.0 mg/25mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous, Oral Feb 1, 2026 In Use
83634-0204-02 83634-0204 Thiotepa Thiotepa 15.0 mg/1.5mL Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine Intracavitary, Intravenous, Intravesical Oct 1, 2025 In Use
83634-0203-74 83634-0203 Fulvestrant Fulvestrant 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Feb 28, 2024 In Use
83634-0202-61 83634-0202 Melphalan hydrochloride Melphalan Hydrochloride Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec 18, 2023 In Use
83513-0010-01 83513-0010 Docetaxel BEIZRAY 20.0 mg/ml Chemotherapy Antimitotic Agent Taxane Intravenous Oct 23, 2024 In Use
83513-0009-01 83513-0009 Docetaxel BEIZRAY 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct 23, 2024 In Use
83457-0012-10 83457-0012 Denosumab OSPOMYV 60.0 mg/mL Ancillary Therapy Monoclonal Antibody RANKL Subcutaneous Oct 10, 2025 In Use
83444-0301-10 83444-0301 Cosibelimab UNLOXCYT 300.0 mg/5mL Immunotherapy Checkpoint Inhibitor PD-L1 Intravenous Jun 30, 2025 In Use
83270-0451-05 83270-0451 ETOPOSIDE ETOPOSIDE 50.0 mg/1 Chemotherapy Plant Alkaloid Epipodophyllotoxins Oral May 29, 2026 In Use
83270-0161-01 83270-0161 Ondansetron hydrochloride Ondansetron hydrochloride 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Sep 30, 2023 In Use
83270-0160-03 83270-0160 Ondansetron hydrochloride Ondansetron hydrochloride 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Sep 30, 2023 In Use
83257-0030-11 83257-0030 Denosumab-kyqq AUKELSO 120.0 mg/1.7mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Jan 5, 2026 In Use
83257-0029-41 83257-0029 Denosumab-kyqq BOSAYA 60.0 mg/mL Ancillary Therapy Monoclonal Antibody RANKL Subcutaneous Jan 5, 2026 In Use
83257-0010-11 83257-0010 Bevacizumab-nwgd JOBEVNE 25.0 mg/mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Apr 10, 2025 In Use
83257-0009-11 83257-0009 Bevacizumab-nwgd JOBEVNE 25.0 mg/mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Apr 10, 2025 In Use
83257-0005-41 83257-0005 Pegfilgrastim-jmdb Fulphila 6.0 mg/.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Oct 1, 2023 In Use
83257-0004-12 83257-0004 Trastuzumab-dkst OGIVRI Immunotherapy Monoclonal Antibody HER2 Oct 1, 2023 In Use
83257-0003-01 83257-0003 Trastuzumab-dkst, Trastuzumab OGIVRI 420.0 mg/20mL Immunotherapy Monoclonal Antibody HER2 Intravenous Oct 1, 2023 In Use
83257-0001-11 83257-0001 Trastuzumab-dkst OGIVRI 150.0 mg/7.4mL Immunotherapy Monoclonal Antibody HER2 Intravenous Oct 1, 2023 In Use
83205-0001-02 83205-0001 Afamitresgene autoleucel TECELRA 10000000000.0 1/1 Immunotherapy T Cell Receptor (TCR) MAGE-A4 Intravenous Aug 2, 2024 In Use
83107-0030-02 83107-0030 Amifostine Ethyol 500.0 mg/10mL Ancillary Therapy Chemoprotective Detoxifying Agent Intravenous Mar 16, 2026 In Use
83090-0010-10 83090-0010 Arsenic trioxide ARSENIC TRIOXIDE 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Nov 9, 2023 In Use
83090-0010-01 83090-0010 Arsenic trioxide ARSENIC TRIOXIDE 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Nov 9, 2023 In Use

Found 12393 results — Export these results